Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more
Market Cap & Net Worth: Mendus AB (publ) (IMMU)
Mendus AB (publ) (ST:IMMU) has a market capitalization of $22.64 Million (Skr254.02 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #29054 globally and #413 in its home market, demonstrating a 3.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mendus AB (publ)'s stock price Skr4.15 by its total outstanding shares 61283415 (61.28 Million).
Mendus AB (publ) Market Cap History: 2015 to 2026
Mendus AB (publ)'s market capitalization history from 2015 to 2026. Data shows change from $3.61 Billion to $22.64 Million (-36.91% CAGR).
Mendus AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mendus AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.44x
Mendus AB (publ)'s market cap is 8.44 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.06 Billion | $16.67 Million | -$135.71 Million | 63.51x | N/A |
| 2021 | $431.22 Million | $6.00K | -$136.69 Million | 71869.62x | N/A |
| 2022 | $242.53 Million | $3.00 Million | -$136.99 Million | 80.98x | N/A |
| 2023 | $57.14 Million | $28.49 Million | -$101.62 Million | 2.01x | N/A |
| 2024 | $42.62 Million | $5.05 Million | -$128.40 Million | 8.44x | N/A |
Competitor Companies of IMMU by Market Capitalization
Companies near Mendus AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to Mendus AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Mendus AB (publ) Historical Marketcap From 2015 to 2026
Between 2015 and today, Mendus AB (publ)'s market cap moved from $3.61 Billion to $ 22.64 Million, with a yearly change of -36.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr22.64 Million | -25.98% |
| 2025 | Skr30.59 Million | -28.21% |
| 2024 | Skr42.62 Million | -25.42% |
| 2023 | Skr57.14 Million | -76.44% |
| 2022 | Skr242.53 Million | -43.76% |
| 2021 | Skr431.22 Million | -42.09% |
| 2020 | Skr744.69 Million | -29.66% |
| 2019 | Skr1.06 Billion | +41.40% |
| 2018 | Skr748.72 Million | +7.23% |
| 2017 | Skr698.24 Million | -69.83% |
| 2016 | Skr2.31 Billion | -35.96% |
| 2015 | Skr3.61 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Mendus AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.64 Million USD |
| MoneyControl | $22.64 Million USD |
| MarketWatch | $22.64 Million USD |
| marketcap.company | $22.64 Million USD |
| Reuters | $22.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.